Compare Novartis AG (NVS) vs Ermenegildo Zegna N.V. Ordinary Shares (ZGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Ermenegildo Zegna N.V. Ordinary Shares — how do they compare? Novartis AG trades at $149.48 (market cap $279.90B), while Ermenegildo Zegna N.V. Ordinary Shares trades at $12.8 (market cap $3.44B). The key difference: Novartis AG is far larger — about 81.4× Ermenegildo Zegna N.V. Ordinary Shares's market cap, and Novartis AG pays the higher dividend (3.23%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Ermenegildo Zegna N.V. Ordinary Shares for 0 Days on average.
| NVS | ZGN | |
|---|---|---|
Market Cap | $279.90B | $3.44B |
Volume | 1,647,300 | 781,107 |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $15.25 |
52-Week Low | $121.80 | $8.69 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $321.22B | $4.40B |
Dividend Yield | 3.23% | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $142.41, down 0.99% with a bearish technical signal despite strong fundamentals including 74.74% gross margins and 30.55% ROE. Recent Q2 2026 EPS beat expectations at $2.41 versus $2.17, though Q1 missed. The company announced a $7.8B licensing deal with China's Abogen for mRNA therapy, while facing clinical setbacks in ALS drug development and investor scrutiny over M&A strategy.
The stock presents a mixed outlook with solid profitability and growth potential from new deals, but technical weakness and recent trial failures pose near-term risks. Analyst consensus at $146 target suggests modest upside, though bearish sentiment from 68% hold ratings indicates caution amid pipeline uncertainties and competitive pressures in pharma.
ZGN trades at $12.94, up 2.7% with a neutral technical outlook. The stock shows mixed fundamentals with a high P/E of 38.5 but strong gross margins of 67.58%. Recent earnings beat expectations in three of the last four quarters, though Q2 2026 missed estimates. Analyst consensus is bullish with a $14.12 price target and 66.7% buy ratings. Revenue growth continues with 2025 reaching $1.92B, though net margins compressed to 3.98%.
ZGN presents a growth opportunity with expanding DTC momentum and margin potential, but faces valuation concerns and competitive pressures. The stock's upside depends on sustained earnings growth and successful execution of the retail-first strategy amidst fashion sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Ermenegildo Zegna N.V. Ordinary Shares
Ermenegildo Zegna N.V. is a luxury fashion group whose brands include Zegna, Thom Browne, and Tom Ford Fashion. The company operates a vertically integrated supply chain, sourcing wool from its own Australian farm through to finished garment production.
Read more on ZGN →
